Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$38.47 USD

38.47
860,382

+0.11 (0.29%)

Updated Aug 7, 2025 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion

by Zacks Equity Research

Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.

Zacks Equity Research

The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic

by Zacks Equity Research

Roche, Wells Fargo, General Aerospace and Key Tronic are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Roche, Wells Fargo & GE Aerospace

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Wells Fargo & Company (WFC) and GE Aerospace (GE), as well as a micro-cap stock Key Tronic Corporation (KTCC).

Zacks Equity Research

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

by Zacks Equity Research

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

Zacks Equity Research

Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

by Zacks Equity Research

Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

by Kinjel Shah

J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.

Zacks Equity Research

Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Zacks Equity Research

Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.

Zacks Equity Research

Regeneron (REGN) Announces Positive Data on Oncology Candidate

by Zacks Equity Research

Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More

by Kinjel Shah

AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.

Zacks Equity Research

Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation

by Zacks Equity Research

Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Zacks Equity Research

The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen

by Zacks Equity Research

Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.

Sundeep Ganoria headshot

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

by Sundeep Ganoria

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

Zacks Equity Research

Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data

by Zacks Equity Research

Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.

Zacks Equity Research

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.

Zacks Equity Research

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

by Zacks Equity Research

Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.

Zacks Equity Research

Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y

by Zacks Equity Research

Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.

Zacks Equity Research

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Zacks Equity Research

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

by Zacks Equity Research

An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.

Zacks Equity Research

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View

by Zacks Equity Research

AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.

Zacks Equity Research

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

by Zacks Equity Research

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Zacks Equity Research

Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

by Zacks Equity Research

Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.

Zacks Equity Research

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

by Kinjel Shah

J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.

Zacks Equity Research

Adaptimmune (ADAP) Down on End of Collaboration With Roche

by Zacks Equity Research

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.